Recent advances in COPD disease management with fixed-dose long-acting combination therapies

References

• Global initiative for chronic Obstructive Lung Disease (GOLD 2014). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2014. Available from: www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdf [Last accessed 22 January 2014]
   Google Scholar
• Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med 2006;119(10 Suppl 1):32-7
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012;40(6):1545-54
   Google Scholar
• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33(5):1165-85
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease − 2008 update − highlights for primary care. Can Respir J 2008;15(Suppl A):1A
   PubMed Web of Science ®Google Scholar
• Cazzola M, Dahl R. Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPD. Chest 2004;126(1):220-37
   PubMed Web of Science ®Google Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23(4):257-67
   PubMed Web of Science ®Google Scholar
• The COMBIVENT Inhalation Solution Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994;105(5):1411-19
   Google Scholar
• Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc 2007;4(7):526-34
   PubMedGoogle Scholar
• Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs 2012;72(2):273-300
   Google Scholar
• O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23(6):832-40
   PubMed Web of Science ®Google Scholar
• Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3(2):205-15
   PubMedGoogle Scholar
• Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res 2006;7:147
   PubMed Web of Science ®Google Scholar
• Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127(3):809-17
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105(3):435-41
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary. Respir Res 2013;14:49
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361(9356):449-56
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21(1):74-81
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22(6):912-19
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;17(4):CD006829
   Google Scholar
• Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 2010;80(2):89-95
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34(3):641-7
   PubMed Web of Science ®Google Scholar
• Yawn BP, Li Y, Tian H, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 2013;8:295-304
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004;1:345-51
   PubMedGoogle Scholar
• Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther 2013;26(1):145-55
   PubMed Web of Science ®Google Scholar
• Johnson M, Rennard S. Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest 2001;120(1):258-70
   PubMed Web of Science ®Google Scholar
• Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30(3):472-8
   Google Scholar
• Trevethick M, Clarke N, Strawbridge M, Yeadon M. Inhaled muscarinic antagonists for COPD – does an anti-inflammatory mechanism really play a role? Curr Opin Pharmacol 2009;9(3):250-5
   PubMed Web of Science ®Google Scholar
• van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centered outcomes. Prim Care Respir J 2012;21(1):101-8
   PubMedGoogle Scholar
• Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42(6):1484-94
   PubMed Web of Science ®Google Scholar
• Beeh K-M, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014; doi:10.1016/j.rmed.2014.01.006. [Epub ahead of print]
   Web of Science ®Google Scholar
• Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J 2013; doi: 10.1183/09031936.00124013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1(1):51-60
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1(3):199-209
   PubMed Web of Science ®Google Scholar
• Dahl R, Gallagher N, Green Y, et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD [abstract P3385]. Eur Respir J 2013;42(Suppl 57):692s
   Google Scholar
• Dahl R, Jadayel D, Alagappan VK, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis 2013;8:501-8
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012;40(5):1106-14
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92
   PubMed Web of Science ®Google Scholar
• Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011;105(4):571-9
   PubMed Web of Science ®Google Scholar
• Ferguson G, Barnes N, Mehta R, et al. Cardio- and cerebro-vascular safety profile Of QVA149 in patients with COPD: a pooled analysis [abstract]. Am J Respir Crit Care Med 2013;187(1):A1488
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01574651. Available from: http://clinicaltrials.gov/ct2/show/NCT01574651
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01610037. Available from: http://clinicaltrials.gov/show/NCT01610037
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01782326. Available from: http://clinicaltrials.gov/show/NCT01782326
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01709903. Available from: http://clinicaltrials.gov/show/NCT01709903
   Google Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014; doi: 10.1378/chest.13-1579. [Epub ahead of print]
   Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 μg in COPD. Respir Med 2013;107(10):1538-46
   PubMed Web of Science ®Google Scholar
• Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD [poster P3640]. Presented at European Respiratory Society Annual Congress; 7-11 September 2013; Barcelona, Spain
   Google Scholar
• Anzueto A, Decramer M, Kaelin T, et al. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium in COPD [poster 42837]. Presented at American Thoracic Society International Conference; 17-22 May 2013; Philadelphia, USA
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01716520. Available from: http://clinicaltrials.gov/show/NCT01716520
   Google Scholar
• GlaxoSmithKline Clinical Study Register. Result summary DB2116133. A randomized, double-blind, 3-way, cross-over study to evaluate lung function response after treatment with umeclidinium 62.5 mcg, vilanterol 25 mcg, and umeclidinium/vilanterol 62.5/25 mcg once-daily in subjects with chronic obstructive pulmonary disease (COPD). 2013. Available from: www.gsk-clinicalstudyregister.com/files2/a4eb7507-0808-4196-b85d-70c63e287917 [Last accessed 5 December 2013]
   Google Scholar
• Maltais F, Singh S, Donald A, et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials [poster P761]. Presented at European Respiraory Society Annual Congess; 7-11 September 2013; Barcelona, Spain
   Google Scholar
• Food and Drug Administration (FDA). FDA Briefing Document. Pulmonary-Allergy Drugs Advisory Committee Meeting. NDA 203-975: umeclidinium and vilanterol inhalation powder for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). 2013. Available from: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ucm367411.pdf [Last accessed 5 December 2013]
   Google Scholar
• Donohue J, Niewoehner D, Brooks J, et al. Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD [poster P760]. Presented at European Respiratory Society Annual Congress; 7-11 September 2013; Barcelona, Spain
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01777334. Available from: http://clinicaltrials.gov/show/NCT01777334
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01899742. Available from: http://clinicaltrials.gov/ct2/show/NCT01899742
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01817764. Available from: http://clinicaltrials.gov/ct2/show/NCT01817764
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01822899. Available from: http://clinicaltrials.gov/ct2/show/NCT01822899
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01879410. Available from: http://clinicaltrials.gov/show/NCT01879410
   Google Scholar
• Reisner C, St Rose E, Strom S, et al. Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [poster P879]. Presented at European Respiratory Society Annual Congress; 24-28 September 2011; Amsterdam, The Netherlands
   Google Scholar
• Reisner C, Fogarty C, Spangenthal S, et al. Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [poster]. Presented at American Thoracic Society International Conference; 13-18 May 2011; Denver, Colorado, USA
   Google Scholar
• Reisner C, Fogarty C, Spangenthal S, et al. Novel combination of glycopyrrolate and formoterol Mdi (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]. Am J Respir Crit Care Med 2011;183(1):A6435
   Google Scholar
• Reisner C, Rennard SI, Fogarty C, et al. Pearl Therapeutics’ combination LAMA/LABA MDI (GFF-MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva® Handihaler®, and Foradil® Aerolizer® in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [poster]. Presented at American Thoracic Society International Conference; 18-23 May 2012; San Francisco, California, USA
   Google Scholar
• Reisner C, Fernandez C, Orevillo C, et al. Pearl Therapeutics’ combination LAMA/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva® HandiHaler® and placebo in patients with COPD [poster]. Presented at American Thoracic Society International Conference; 18-23 May 2012; San Francisco, California, USA
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01854645. Available from: http://clinicaltrials.gov/show/NCT01854645
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01854658. Available from: http://clinicaltrials.gov/show/NCT01854658
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01970878. Available from: http://clinicaltrials.gov/ct2/show/NCT01970878
   Google Scholar
• Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract 5557]. Eur Respir J 2010;36(Suppl 54):1014s
   Google Scholar
• Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD [Poster P2882]. Presented at European Respiratory Society Annual Congress; 1-5 September 2012; Vienna, Austria
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01431274. Available from: http://clinicaltrials.gov/show/NCT01431274
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01431287. Available from: http://clinicaltrials.gov/show/NCT01431287
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01969721. Available from: http://clinicaltrials.gov/ct2/show/NCT01969721
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01533935. Available from: http://clinicaltrials.gov/show/NCT01533935
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01533922. Available from: http://clinicaltrials.gov/show/NCT01533922
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01525615. Available from: http://clinicaltrials.gov/show/NCT01525615
   Google Scholar
• Śliwiński P, Perng D-W, Chuchalin A, Jones PW. Efficacy and safety of once-daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [abstract P137]. Thorax 2010;65(Suppl 4):A136
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01437397. Available from: http://clinicaltrials.gov/show/NCT01437397
   Google Scholar
• Almirall. Press Release: Almirall and Forest Laboratories announce positive results of a Phase III Study for aclidinium and formoterol combination in COPD. 2013. Available from: www.almirall.com/webcorp2/cda/comunicacion_detalle_noticia.jsp?id=2500 [Last accessed 10 January 2014]
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01572792. Available from: http://clinicaltrials.gov/show/NCT01572792
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01908140. Available from: http://clinicaltrials.gov/ct2/show/NCT01908140
   Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002;19(1):182-91
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25µg; 100/25µg) on lung function in COPD. Respir Med 2013;107(4):560-9
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Boscia JA, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 µg) improves lung function in COPD: a randomised trial. Respir Med 2013;107(4):550-9
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1(3):210-23
   PubMed Web of Science ®Google Scholar
• Agusti A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014;43(3):763-72
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT01627327. Available from: http://clinicaltrials.gov/show/NCT01627327
   Google Scholar
• GlaxoSmithKline Clinical Study Register. Result summary HZC115805. A 12-week study to evaluate the 24-hour pulmonary function profile of fluticasone furoate/vilanterol (FF/VI) inhalation powder 100/25mcg once-daily via a novel dry powder inhaler compared with tiotropium bromide inhalation powder 18mcg delivered once-daily via the HandiHaler in subjects with chronic obstructive pulmonary disease (COPD) who have or are at risk for co-morbid cardiovascular disease. Available from: www.gsk-clinicalstudyregister.com/study/115805?study_ids=115805#rs [Last accessed 14 January 2014]
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01551758. Available from: http://clinicaltrials.gov/show/NCT01551758
   Google Scholar
• Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013;41(5):1017-22
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01313676. Available from: http://clinicaltrials.gov/ct2/show/NCT01313676
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01706328. Available from: http://clinicaltrials.gov/show/NCT01706328
   Google Scholar
• Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 2012;7:73-86
   PubMed Web of Science ®Google Scholar
• Calverley PM, Kuna P, Monsó E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med 2010;104(12):1858-68
   PubMed Web of Science ®Google Scholar
• Tzani P, Crisafulli E, Nicolini G, et al. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis 2011;6:503-9
   PubMed Web of Science ®Google Scholar
• Agusti A, Corradi M, Cohuet G, et al. FORWARD: a study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations [abstract P762]. Eur Respir J 2013;42(Suppl 57):141s
   Google Scholar
• ClinicalTrials.gov Identifier: NCT00929851. Available from: http://clinicaltrials.gov/show/NCT00929851
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01245569. Available from: http://clinicaltrials.gov/ct2/show/NCT01245569
   Google Scholar
• Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011;14:486-96
   PubMedGoogle Scholar
• Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis 2011;6:353-63
   PubMed Web of Science ®Google Scholar
• Colthorpe P, Voshaar T, Kiekbusch T, et al. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess 2013;2:11-16
   PubMedGoogle Scholar
• Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010;26:2527-33
   PubMed Web of Science ®Google Scholar
• Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 2013;13:72
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Niederlaender C. The Genuair® inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract 2012;66:309-17
   PubMed Web of Science ®Google Scholar
• Anderson P. Use of Respimat® Soft Mist™ inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006;1:251-9
   PubMedGoogle Scholar
• Newman SP. Inhaler treatment options in COPD. Eur Respir Rev 2005;14:102-8
   Google Scholar
• Witek TJ Jr., Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21(2):267-72
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014;189:250-5
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008;31(5):927-33
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic Obstructive Lung Disease (GOLD 2007). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2007. Available from: www.goldcopd.org/Guidelines/guidelines-global-strategy-for-diagnosis-management-2007.html [Last accessed 10 January 2014]
   Google Scholar
• Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012;106(7):989-97
   PubMed Web of Science ®Google Scholar
• Small M, Broomfield S, Higgins V. Quantification and treatment patterns of real-world patients classified by the GOLD 2011 strategy [abstract P185]. Thorax 2012;67(Suppl 2):A144-5
   Google Scholar
• Jochmann A, Neubauer F, Miedinger D, et al. General practitioner’s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly 2010. [Epub ahead of print]
   Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146(8):545-55
   PubMed Web of Science ®Google Scholar
• Singh D, Brooks J, Hagan G, et al. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63:592-8
   PubMed Web of Science ®Google Scholar
• Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(8):741-50
   PubMed Web of Science ®Google Scholar
• Pasqua F, Biscione G, Crigna G, et al. Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. Respir Med 2010;104(3):412-17
   PubMed Web of Science ®Google Scholar
• Karner C, Cates CJ. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; CD008532
   Google Scholar
• Bateman ED, Kornmann O, Ambery C, Norris V. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther 2013;26(5):581-7
   PubMed Web of Science ®Google Scholar
• Wielders PL, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J 2013;42(4):972-81
   PubMed Web of Science ®Google Scholar
• Patel S, Marshall S, Summerhill S, et al. The in-vitro pharmacology of PF-4348235 at native receptors - a novel inhaled dual antimuscarinic/beta2 adrenoceptor agonist [abstract]. Am J Respir Crit Care Med 2011;183(1):A1608
   Google Scholar
• Philip J, Gray A, Clarke N, et al. Demonstration of dual pharmacology in vivo of PF-3429281: a novel inhaled dual antimuscarinic/beta2 agonist [abstract P1231]. Eur Respir J 2010;36(Suppl 54):218s
   PubMedGoogle Scholar
• Steinfeld T, Hughes AD, Klein U, et al. THRX-198321 is a bifunctional muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 2011;79(3):389-99
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(10):948-55
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137(1):20-30
   PubMed Web of Science ®Google Scholar
• White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease. Chest 2013;144(3):758-65
   PubMed Web of Science ®Google Scholar
• Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47(12):2554-60
   PubMed Web of Science ®Google Scholar
• Rutten FH, Zuithoff N, Hak E, et al. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170(10):880-7
   PubMed Web of Science ®Google Scholar
• Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29(2):279-83
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-54
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182(5):598-604
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128-38
   PubMed Web of Science ®Google Scholar
• Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7(5):e37483
   PubMed Web of Science ®Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365(13):1184-92
   PubMed Web of Science ®Google Scholar
• Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:44-52
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur Respir J 2012;40(3):724-41
   PubMed Web of Science ®Google Scholar
• D’Urzo A. Optimizing the management of chronic obstructive pulmonary disease: applying the GOLD strategy. Clin Pract 2013;10(4):481-92
   Google Scholar
• Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs 2014;74:465-88
   PubMed Web of Science ®Google Scholar
• Welte T, Dahl R, Chen H, et al. Once-daily QVA149 improves symptom scores in patients with COPD [abstract P3637]. Eur Respir J 2013;42(Suppl 57):750s
   Google Scholar
• Banerji D, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: the IGNITE trials [abstract P3388]. Eur Respir J 2013;42(Suppl 57):693s
   Google Scholar
• Barnes N, Hashimoto S, Nagase T, et al. QVA149 provides superior peak lung function in patients with COPD [abstract P3634]. Eur Respir J 2013;42(Suppl 57):749s
   Google Scholar
• Bateman ED, Ferguson GT, Welte T, et al. Dual bronchodilation with once-daily QVA149 significantly improves lung function versus single bronchodilators and salmeterol/fluticasone [abstract]. Am J Respir Crit Care Med 2013;187(1):A4271
   Google Scholar
• Welte T, Gallagher N, Green Y, et al. Dual bronchodilation with once-daily QVA149 provides significantly improved clinical outcomes versus mono-bronchodilator therapy: the SHINE study [abstract]. Am J Respir Crit Care Med 2013;187(1):A4272
   Google Scholar
• Vogelmeier C, Bateman ED, Chen H, Banerji D. Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study [abstract P237]. Thorax 2013;68(Suppl 3):A184-5
   Google Scholar
• GlaxoSmithKline. FDA Advisory Committee Briefing Document. ANORO™ ELLIPTA™ (umeclidinium bromide/vilanterol inhalation powder) for treatment of chronic obstructive pulmonary disease. NDA 203975. Presented to Pulmonary-Allergy Drug Advisory Committee. 2013. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM367414.pdf [Last accessed 5 December 2013]
   Google Scholar
• GlaxoSmithKline Clinical Study Register. Result summary DB2116844. Results report for a meta-analysis of DB2113360 and DB2113374: an integrated review of transitional dyspnoea index data for umeclidinium/vilanterol, umeclidinium, vilanterol and tiotropium over 24 weeks in subjects with COPD. 2013. Available from: www.gsk-clinicalstudyregister.com/files2/1f37e00a-6090-4648-9a79-4e49e481af40 [Last accessed 5 December 2013]
   Google Scholar